Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Job Description: Material Scientist – PCB Materials (m/f/d) Role Overview: Huntsman’s Advanced Materials division is looking for a Material Scientist to join our Product Innovation team in Basel, Switzerland. In this role, you will develop advanced materials for
Job Description: Laboratory Technician – PCB Materials (m/f/d) Role Overview: We are looking for a Laboratory Technician – PCB Materials to join the Technology Department within our Advanced Materials division at the Advanced Materials Innovation Center in Basel,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Description : Material Scientist – PCB Materials (m/f/d) Role Overview: Huntsman’s Advanced Materials division is looking for a Material Scientist to join our Product Innovation team in Basel, Switzerland. In this role, you will develop advanced materials for
Description : Laboratory Technician – PCB Materials (m/f/d) Role Overview: We are looking for a Laboratory Technician – PCB Materials to join the Technology Department within our Advanced Materials division at the Advanced Materials Innovation Center in Basel,
BeOne continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)